Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-08-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and usage of funds raised by Kunming Pharmaceutical Group Co., Ltd. It includes extensive data on fundraising amounts, usage, investment projects, and compliance with regulatory requirements related to fundraising. The document references specific regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. It contains detailed financial figures, project investment progress, and audit confirmations related to fundraising activities. The document is not an announcement of a report but the report itself, given its length (15,000 characters) and detailed content. It is not a general annual or interim financial report but a specialized report focused on the use and management of raised capital. This matches the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2021-08-13 Chinese
昆药集团关于2021年度第一期超短期融资券兑付完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of payment (redemption) of a short-term financing bond issued by the company. It details the issuance date, bond terms, and confirmation that the principal and interest have been paid to bondholders. There is no financial statement or detailed financial analysis, but rather an update on a financing activity. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and debt repayment activities.
2021-07-20 Chinese
昆药集团非金融企业债务融资工具信息披露管理制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal management system for information disclosure related to non-financial corporate debt financing instruments issued by Kunming Pharmaceutical Corporation. It outlines principles, responsibilities, procedures, and regulatory compliance for disclosure of financial and operational information during the issuance and life of debt instruments. It references regulatory bodies like the People's Bank of China and the China Interbank Market Dealers Association, and includes detailed rules on periodic reports, major event disclosures, confidentiality, and accountability. The document is not a financial report itself (like an annual or interim report), nor is it an announcement or a certification. It is a governance and compliance manual related to disclosure practices for debt financing instruments. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory compliance document that does not fit other specific categories.
2021-06-30 Chinese
昆药集团九届四十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the approval of an internal management system related to disclosure of non-financial enterprise debt financing instruments. The document is short (617 characters) and is an official announcement of a board decision, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory filing or certification. The content fits best under Board/Management Information (MANG) as it announces a board resolution and decision.
2021-06-30 Chinese
昆药集团关于使用部分闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Corporation regarding the progress of using part of its idle funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, expected yields, risk control measures, and the impact on the company. The document is not a full financial report but rather a regulatory announcement about capital management activities involving financial investments. It does not contain comprehensive financial statements or quarterly/yearly financial results. The document length is 7855 characters, which is substantial but the content is focused on capital usage and investment updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-06-30 Chinese
昆药集团关于全资子公司参与第五批全国药品集中采购拟中标的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary's participation and tentative selection in the fifth batch of national centralized drug procurement. It details the product involved, its specifications, expected procurement volume, price, and the impact on the company's sales and market position. The document includes a risk warning about uncertainties in contract signing and implementation. There are no financial statements, no detailed financial performance data, no regulatory certifications, or meeting materials. The document is an announcement of a business event related to procurement and sales impact, not a financial report or regulatory filing. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-06-23 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.